Table 1: Characteristics of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment.

Capecitabine/irinotecan ()Capecitabine/irinotecan + cetuximab () value

Gender, (%)
Male29 (78)33 (67)
Female8 (22)16 (33)
Fisher’s exact test0.33

Age (years); median (range)60 (34–82)57 (33–80)
Unpaired -test0.79

Clinical TNM stage, (%)
cT10 (0)0 (0)
cT24 (11)9 (18)
cT328 (76)36 (73)
cT44 (11)4 (8)
cTx 1 (3)0 (0)
Chi square0.62
cN−6 (16)15 (31)
cN+31 (84)34 (69)
Fisher’s exact test0.14

Tumor distance from anal verge (cm); median (range)6 (2–13)7 (0–13)
Unpaired -test0.77

KRAS status, (%)
KRAS wild-typen.a.32 (65)
KRAS mutation n.a.13 (27)
KRAS unknownn.a.4 (8)

Surgical technique
Low anterior resection3141
Abdominoperineal resection67
Hartmann’s operation01
Chi square0.67

Time to resection (days), median (range)39 (21–79)38 (21–67)
Unpaired -test0.94

n.a.: not applicable.